The write down comes after emraclidine missed crucial goals in two mid-stage trials, prompting AbbVie to reassess the drug’s value. In November, the company revealed that the drug failed to meet key milestones in clinical studies.
Once seen as a breakthrough treatment for schizophrenia, AbbVie has now significantly reduced its cashflows from the product.
As part of its review, the company is also assessing other assets tied to the Cereval deal, including tavapadon, a candidate drug that recently met key objectives in a late-stage Parkinson’s disease study, according to the Journal.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
